On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
Notably, Jazz Pharmaceuticals hit its 52-week low of $130.15 on December 20, 2017.
In November, Jazz Pharmaceuticals submitted an MAA (Marketing Authorization Application) to the European Medicines Agency for the approval of solriamfetol. Solrianfetol aims to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. Jazz Pharmaceuticals’ MAA has been supported with data from the TONES Phase 3 program. Solriamfetol’s approval could boost Jazz Pharmaceuticals’ revenue growth in 2019.
Financial outlook for 2018
Jazz Pharmaceuticals expects the net revenues for 2018 to be $1.86 billion–$1.90 billion. The company expects a GAAP gross margin of ~93.0% in 2018.
Jazz Pharmaceuticals expects the GAAP diluted EPS to be $5.70–$6.90 in 2018. Jazz Pharmaceuticals provided a non-GAAP diluted EPS guidance range of $12.75–$13.25.
Of 19 analysts tracking Jazz Pharmaceuticals in November, five recommended a “strong buy,” nine recommended a “buy,” and five recommended a “hold.”
On November 13, Jazz Pharmaceuticals had a consensus 12-month target price of $188.5, which represents an ~26.90% return on investment over the next 12 months.
In November, among the 17 analysts tracking Alnylam Pharmaceuticals (ALNY), ~82% recommended a “buy.” Among the eight analysts tracking Amicus Therapeutics (FOLD), ~63% recommended a “buy.” Among the 26 analysts tracking Regeneron Pharmaceuticals (REGN), ~31% recommended a “buy.”
On November 13, Alnylam Pharmaceuticals (ALNY), Amicus Therapeutics (FOLD), and Regeneron Pharmaceuticals (REGN) had consensus 12-month target prices of $132.41, $18.5, and $410.05, respectively. The target prices indicate a return on investment of ~94.95%, ~82.99% and ~18.32% over the next 12 months.